Trust Co. of Vermont Buys Shares of 31,406 Stryker Corporation $SYK

Trust Co. of Vermont bought a new position in Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 31,406 shares of the medical technology company’s stock, valued at approximately $9,888,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Stryker by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock valued at $11,917,396,000 after purchasing an additional 133,892 shares during the period. State Street Corp increased its stake in Stryker by 2.1% during the 4th quarter. State Street Corp now owns 15,254,407 shares of the medical technology company’s stock worth $5,374,731,000 after purchasing an additional 311,507 shares in the last quarter. Geode Capital Management LLC raised its holdings in Stryker by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock worth $2,636,238,000 after buying an additional 69,851 shares during the period. Wellington Management Group LLP lifted its stake in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after buying an additional 1,198,665 shares in the last quarter. Finally, Norges Bank bought a new position in Stryker in the fourth quarter valued at approximately $1,822,272,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on SYK. Citizens Jmp lowered their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. BTIG Research cut their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. JPMorgan Chase & Co. dropped their price target on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Barclays cut their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $386.28.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.60% of the company’s stock.

Stryker Price Performance

NYSE SYK opened at $331.75 on Tuesday. The firm’s 50 day moving average is $325.21 and its 200-day moving average is $333.24. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $127.25 billion, a PE ratio of 34.38, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio is currently 36.48%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.